Navigation Links
Gloucester Pharmaceuticals Reports Positive Interim Phase II Data,on Romidepsin for T-Cell Lymphomas at the 2007 American Society of,Clinical Oncology Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, today announced that data for romidepsin as a treatment for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL. The data presented are part of an interim analysis of a phase II study of romidepsin sponsored by the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with Gloucester.

Data from the NCI's ongoing clinical trial of romidepsin was presented in Abstract #8027 "Phase II Trial of Depsipeptide in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma" on Monday, June 4th.

The interim results reported on 70 patients with CTCL and 39 patients with PTCL. In the CTCL patient group 4 of 70 patients, or 6%, achieved a complete response, with the duration of response ranging from 8 to 63+ months. A partial response was observed in 18 of 70 patients, or 26%, with the duration of response ranging from 1 to 69+ months. The most common adverse events reported were nausea, vomiting, fatigue, transient granulocytopenia and thrombocytopenia, and anorexia.

Commenting on the data from the NCI's study, William McCulloch, M.B., FRCP, Executive Vice President and Chief Medical Officer at Gloucester said, "Clinical evidence for romidepsin's value in the treatment of T-cell lymphomas continues to build. Based on the data from this trial, as well as interim data from our own Gloucester-sponsored CTCL pivotal phase II study which is nearing completion, we remain enthusiastic about the clinical prospects for romidepsin."

In the PTCL patient group 3 of 39 patients, or 7%, achieved a complete response, with the duration of response ranging from 9 to 43+ months. A partial respons
'"/>




Page: 1 2 3

Related medicine technology :

1. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
2. Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib Combination in Non-Small Cell Lung Cancer Presented at American Association of Cancer Research Annual Meeting
3. Gloucester Pharmaceuticals Announces Multiple Presentations of Preclinical Romidepsin Data at American Association of Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:9/19/2014)... September 19, 2014 ... announced the addition of the "Global ... their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... broadly classified into wide categories based on ... the treatment of different gynecological conditions that ...
(Date:9/19/2014)... -- 4WEB Medical announces the formal launch of the ... on the market today at this weekend,s American ... Chicago .  The Osteotomy Truss System is a ... 74 size options included in one versatile set. Previously ... to 18 implant sizes, which limited a surgeon,s ability ...
(Date:9/19/2014)... NORWALK, Conn. , Sept. 19, 2014 ... , a leading online community to help oncologists ... newest information available regarding the use of targeted therapies ... blood cancer research and treatment.  Every ... as a way to raise awareness about blood cancers—helping ...
Breaking Medicine Technology:Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 34WEB Medical Unveils 3D-Printed Osteotomy Truss System 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4
... Trial Opening in 13 New Sites, BERKELEY ... GNTA ) announced that the French Health Products,Safety ... Company,s,Phase 3 trial of Genasense(R) (oblimersen sodium) Injection, ... This authorization,enables the opening of approximately 13 new ...
... DIEGO, Oct. 17 Vical Incorporated,(Nasdaq: VICL ) ... found no safety issues and recommended continuation of the,company,s ... (CMV). The,DSMB completed an interim evaluation of safety data ... stem cell transplant (HCT),recipients enrolled in the study. ...
Cached Medicine Technology:Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency 2Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency 3Interim Safety Data Favorable for Vical's Phase 2 Trial of DNA Vaccine Against CMV 2Interim Safety Data Favorable for Vical's Phase 2 Trial of DNA Vaccine Against CMV 3Interim Safety Data Favorable for Vical's Phase 2 Trial of DNA Vaccine Against CMV 4
(Date:9/21/2014)... St. Petersburg, FL (PRWEB) September 22, 2014 ... Beauty® outlines the top 3: , 1) Dry Brushing improves ... 2) Dry Skin Brushing exfoliates dead cells, toxins and debris ... with lymphatic drainage and movement , While Body Brushing can ... facial skin. Because it is more fragile and thinner, ...
(Date:9/21/2014)... birth the birth of an infant prior to ... problem that has increased over the past two decades. ... Prevention (CDC), preterm birth affects nearly 500,000 babies each ... U.S. While medical care has improved survival rates for ... the neurodevelopmental outcomes of preterm infants. , Research led ...
(Date:9/21/2014)... Instituting a partial smoking ban at a homeless shelter ... levels, an indicator of exposure to cigarette smoke, and ... to new research. The University of Texas Health Science ... week in the journal Addictive Behaviors . , ... fallen to 18 percent among adults, but among homeless ...
(Date:9/21/2014)... Dallas, Texas (PRWEB) September 22, 2014 ... was originally launched in 1997, and is used ... children and adults. Its active ingredient, budesonide, is ... the corticosteroid receptor. AstraZeneca’s Pulmicort franchise includes the ... older than six years of age, Pulmicort Respules ...
(Date:9/21/2014)... authorities focus on the physical activity benefits of active ... reveals that for children, playing has no goal ... is fun, done alone or with friends, and it ... also to combat boredom, sadness, fear, or loneliness." "By ... put aside several aspects of play that are beneficial ...
Breaking Medicine News(10 mins):Health News:Gorgeous Skin: 3 Top Benefits of Dry Face Brushing from Sublime Beauty® 2Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 2Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 3Health News:UTHealth researchers study impact of smoking ban in homeless shelter 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Narrow focus on physical activity could be ruining kids' playtime 2
... wristbands had much less nausea while receiving radiation treatment, ... medication, according to a study published in the ... of Rochester Medical Center researchers. , Previous research ... outcome related to your body that you expect to ...
... focus on costly problemNASHVILLE, Tenn., April 8 MedSolutions ... cost management services that help health plans control diagnostic ... a recent Journal of the American Medical Association ... to address the growing issue of diagnostic errors.In their ...
... and wellness resources , , MINNEAPOLIS, ... FIT ) today announced a partnership with the state ... management program for more than 17,000 state employees. ... Neb. Gov. Dave Heineman outlined the program at a ...
... Washington University in St. Louis has found that students who participated in the Experience Corps tutoring program, ... , Click here for more information. ... , , , ... , , , ...
... European Society of Cardiology Council on Cardiovascular Nursing and ... Nurses Cardiovascular Association (INCA), is being held at the ... , The meeting - considered by many to be ... professionals - will show case the latest advances in ...
... functional food manufacturers unique ,superfruits, opportunityPURCHASE, N.Y., April ... Polyphenols has attained self-affirmed GRAS status. An ... a comprehensive evaluation of research and toxicology data. ... for use in food products and supplements. Oligonol(R), ...
Cached Medicine News:Health News:Wristbands ease nausea with cancer treatment 2Health News:MedSolutions Joins Call for Increased Attention on Diagnostic Errors 2Health News:MedSolutions Joins Call for Increased Attention on Diagnostic Errors 3Health News:HealthFitness Announces New Employee Health Partnership With State of Nebraska 2Health News:Study finds students with Experience Corps tutors make 60 percent more progress in critical reading skills 2Health News:Study finds students with Experience Corps tutors make 60 percent more progress in critical reading skills 3Health News:Study finds students with Experience Corps tutors make 60 percent more progress in critical reading skills 4Health News:Study finds students with Experience Corps tutors make 60 percent more progress in critical reading skills 5Health News:Study finds students with Experience Corps tutors make 60 percent more progress in critical reading skills 6Health News:Telemonitoring changes the working practice of cardiac nurses 2Health News:Telemonitoring changes the working practice of cardiac nurses 3Health News:Telemonitoring changes the working practice of cardiac nurses 4Health News:Telemonitoring changes the working practice of cardiac nurses 5Health News:Telemonitoring changes the working practice of cardiac nurses 6Health News:Oligonol(R) Lychee Fruit Polyphenols Attains Self-Affirmed GRAS (Generally Recognized As Safe) Status 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: